PROGRAM SNAPSHOT

Encellin — ENCRT-103-hPI

🔬 Emerging Contender Company-Reported

Early interim data on an encapsulated-islet device designed to avoid the scarring that has sunk earlier encapsulation attempts.

What's actually shown: Phase 1 interim results, reported January 2026 — early non-fibrotic engraftment and viable encapsulated human islets in trial subjects.
Last verified: 2026-08-24. Sources: Encellin press release.

This is a Program Snapshot, not yet a full Trial Report Card — a full Report Card means the deeper eligibility, risk, and enrollment research we do for each Cure Radar post. Follow @t1dcureintelligence for the full breakdown when this program gets its own deep-dive.

← Back to the full leaderboard